Ipsen Hungry For More Deals After Swallowing Epizyme
$247m Upfront For Lymphoma Drug Tazverik
Executive Summary
Ipsen CEO David Loew recently told Scrip that a return to more rational valuations for biotechs should led to more deals. The Epizyme acquisition could be the first of many by the French group this year.
You may also be interested in...
Ipsen's Desire For Dealmaking Burns Bright
CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."
Business Development Remains Top Priority For Ipsen
CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.
Ipsen’s Onivyde Hits Bullseye In Pivotal First-Line Pancreatic Cancer Trial
The French firm’s Onivyde has succeeded as part of a combination regimen in chemotherapy-naïve pancreatic cancer patients, setting it up for a label expansion, but some experts are keen to see survival data in full before raising guidance.